CRECON MEDICAL ASSESSMENT

JP

Presentations

Presentation

  • Kamae I, Kitamura A, Sakurai M, Yamamoto M, Inoue S, Shibahara H, Kobayashi M. ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 9, 2018.

  • Kitamura A, Sato T, Priest V, Inoue S, Kobayashi M. COST-MINIMIZATION ANALYSIS OF VERCISE DBS SYSTEM FOR PARKINSON’S DISEASE IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 9, 2018.

  • Kamae I, Kobayashi M, Patel P, Neumann PJ. Japanese HTA and Pricing: Current Methods and Future Potential. ISPOR Asia-Pacific Conference, Tokyo, Japan. Workshop Presentation. Sep 10, 2018.

  • Ikeda S, Kobayashi M, Wong-Rieger D. How Will Patient Centricity Be Captured in the Japanese HTA and Healthcare Reform? ISPOR Asia-Pacific Conference, Tokyo, Japan. Issue Panel Presentation. Sep 9, 2018.

  • Kim S, Kobayashi M, Xuan j, Ko B. REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC? ISPOR 2018 Baltimore, MD, USA. 22th May, 2018.

  • Xuan J, Liu L, Kobayashi M, Lee S. ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK. ISPOR 2018 Baltimore, MD, USA. 21th May, 2018

  • Kobayashi M. The trial intorduction of cost-effectiveness evaluation and future prospects in japan. 5th seminar of the center of pharmacoeconomics and QOL research at Niigata University of health and welfare. Niigata University of health and welfare, Niigata, Japan. 10th Mar, 2018. (in Japanese)

  • Murata T, Suzukamo Y, Shiroiwa T, Shimozuma K, Ohashi Y, Mukai H. Response shift analysis of QOL in SELECT-BC using Taxane and TS-1 for metastasis and recurrent breast cancer patients. 5th QOL/PRO research academic meeting, Okayama, Japan. Dec 2, 2017.

  • Mishina S, Murata T. Medical Cost Evaluation of Apixaban versus Warfarin in Patients with Non valvular Atrial Fibrillation: Japanese Claims Database Analysis. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 4-8, 2017.

  • Yamabe K, Kuwabara H, Inoue S, Kobayashi M. Burden Of Ulcerative Colitis In Japan. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 6, 2017.

TOPPresentation
TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA